Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -123.23% is 26% above its 5-year average of -166.29%, near the high end of its 5-year range (-410.24%–-54.46%).
19.64% above its 12-month average of -153.35%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -7.47%.
RETURN ON ASSETS (ROA)
-123.23%
RETURN ON ASSETS (ROA) AVG TTM
-153.35%
RETURN ON ASSETS (ROA) AVG 3Y
-205.77%
RETURN ON ASSETS (ROA) AVG 5Y
-166.29%
RETURN ON ASSETS (ROA) AVG 10Y
-177.30%
RETURN ON ASSETS (ROA) AVG 15Y
-121.59%
RETURN ON ASSETS (ROA) AVG 20Y
-127.97%
CURRENT VS TTM AVG
+19.64%
CURRENT VS 3Y AVG
+40.11%
CURRENT VS 5Y AVG
+25.90%
CURRENT VS 10Y AVG
+30.49%
CURRENT VS 15Y AVG
-1.34%
CURRENT VS 20Y AVG
+3.70%
SECTOR MEDIAN · HEALTHCARE
-28.05%
median of 558 covered companies
CURRENT VS SECTOR MEDIAN
-339.40%
vs the sector median at left
Vyome Holdings, Inc.
Market Cap
$13.48M
Return on Assets (ROA)
-123.23%
TTM Avg
-153.35%
3Y Avg
-205.77%
5Y Avg
-166.29%
Market Cap
$13.91M
Return on Assets (ROA)
-85.85%
TTM Avg
-102.78%
3Y Avg
-95.22%
5Y Avg
-76.09%
Market Cap
$13.26M
Return on Assets (ROA)
-60.93%
TTM Avg
-160.25%
3Y Avg
-205.49%
5Y Avg
-152.09%
Market Cap
$14.14M
Return on Assets (ROA)
-32.53%
TTM Avg
-31.07%
3Y Avg
-30.77%
5Y Avg
-29.89%
Market Cap
$12.74M
Return on Assets (ROA)
-49.12%
TTM Avg
-29.80%
3Y Avg
-67.98%
5Y Avg
-117.36%
Market Cap
$15.18M
Return on Assets (ROA)
-201.89%
TTM Avg
-113.65%
3Y Avg
-83.24%
5Y Avg
-72.72%
Market Cap
$12.12M
Return on Assets (ROA)
-13.01%
TTM Avg
-15.22%
3Y Avg
-24.53%
5Y Avg
-20.43%
Market Cap
$15.39M
Return on Assets (ROA)
-41.18%
TTM Avg
-60.23%
3Y Avg
-53.11%
5Y Avg
-40.22%
Market Cap
$15.44M
Return on Assets (ROA)
-213.77%
TTM Avg
-110.51%
3Y Avg
-93.41%
5Y Avg
-68.22%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vyome Holdings, Inc. (HIND) | $13.48M | -123.23% | -153.35% | -205.77% | -166.29% |
| IN8bio, Inc. (INAB)vs › | $13.91M | -85.85% | -102.78% | -95.22% | -76.09% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $13.26M | -60.93% | -160.25% | -205.49% | -152.09% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.14M | -32.53% | -31.07% | -30.77% | -29.89% |
| Dare Bioscience, Inc. (DARE)vs › | $12.74M | -49.12% | -29.80% | -67.98% | -117.36% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.18M | -201.89% | -113.65% | -83.24% | -72.72% |
| IRIDEX Corporation (IRIX)vs › | $12.12M | -13.01% | -15.22% | -24.53% | -20.43% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.39M | -41.18% | -60.23% | -53.11% | -40.22% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.44M | -213.77% | -110.51% | -93.41% | -68.22% |
| Lantern Pharma Inc. (LTRN)vs › | $11.83M | -216.84% | -118.20% | -6127.40% | -4092.56% |
ROA
-123.2%
ROE
-186.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -157.95% |
| 2024-12-31 | -148.76% |
| 2023-12-31 | -106.15% |
| 2022-12-31 | -410.24% |
| 2021-12-31 | -120.21% |
| 2020-12-31 | -54.46% |
| 2019-12-31 | -187.13% |
| 2018-12-31 | -175.38% |
| 2017-12-31 | -38.12% |
| 2016-12-31 | -331.78% |
| 2015-12-31 | -220.07% |
| 2014-12-31 | -181.63% |
| 2013-12-31 | -97.70% |
| 2012-12-31 | -89.90% |
| 2011-12-31 | -80.03% |
| 2010-12-31 | -44.84% |
| 2009-12-31 | -196.92% |
| 2008-12-31 | -133.93% |
| 2007-12-31 | -48.39% |
| 2006-12-31 | -49.05% |
| 2005-12-31 | -97.01% |
| 2004-12-31 | 0.00% |
| 2003-12-31 | -265.13% |
